VIROLOGIE is a prominent international journal dedicated to advancing the field of virology and infectious diseases, published by John Libbey Eurotext Ltd. Since its inception in 1997, this journal has provided a platform for researchers and professionals to disseminate their findings on various aspects of virology, including the pathogenesis, epidemiology, and treatment of viral infections. Despite its current ranking in Q4 for both Infectious Diseases and Virology categories, the journal remains a valuable resource for emerging research and novel insights. The ISSN for the journal is 1267-8694, and it is based in France. VIROLOGIE is committed to upholding rigorous academic standards and fosters an inclusive scholarly community, making it an essential read for those pursuing knowledge and advancements in the ever-evolving landscape of virology. While the journal does not currently offer open access options, it continues to contribute significantly to the global discourse on viral research through its diverse range of published studies.

JOURNAL OF MEDICAL VIROLOGY is a prestigious academic publication dedicated to advancing the field of virology and infectious diseases. Published by WILEY, this journal has established itself as a cornerstone within the scientific community since its inception in 1977, and it will continue to provide cutting-edge research until 2024. With an impressive impact factor that places it in the Q1 quartile for both Infectious Diseases and Virology, the journal ranks 14 out of 344 in Medicine - Infectious Diseases and 6 out of 80 in Immunology and Microbiology - Virology according to Scopus metrics. Its focus encompasses a broad spectrum of topics, including viral pathogenesis, diagnostics, treatment strategies, and epidemiology, making it an essential resource for researchers, clinicians, and students alike. Although not an open-access journal, it provides valuable insights and accessible content for subscribers and libraries. The ongoing commitment to high-quality peer-reviewed articles makes JOURNAL OF MEDICAL VIROLOGY a vital platform for disseminating knowledge and fostering innovation in virology and related fields.

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA is a distinguished academic journal published by AKADEMIAI KIADO ZRT, focusing on significant advancements in the fields of microbiology, immunology, and infectious diseases. Established in 1994, this journal serves as a vital platform for researchers, professionals, and students keen on exploring the complexities of microbial interactions and immune responses. With a current Impact Factor reflecting its rank within the Q3 categories for Immunology, Microbiology, and Infectious Diseases, it retains a critical position in disseminating innovative research. Although not open access, the journal provides extensive insights disseminated through various academic databases, ensuring a broad reach within the scholarly community. Its convergence over three decades indicates a robust commitment to excellence in scientific inquiry and knowledge sharing. As it moves towards the future, ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA continues to uphold its legacy of fostering collaborative research initiatives that contribute to the understanding and treatment of microbial diseases globally.

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.

Influenza and Other Respiratory Viruses, published by WILEY, serves as a prominent peer-reviewed platform for the dissemination of research contributing to the understanding and management of respiratory viral infections. With an impressive impact factor and established as an Open Access journal since 2014, it ensures maximum visibility and accessibility of pivotal research findings in the realm of Epidemiology, Infectious Diseases, Public Health, and Pulmonary and Respiratory Medicine. Registered under the ISSN 1750-2640 and E-ISSN 1750-2659, the journal boasts Q1 rankings in four critical categories as of 2023, underscoring its significance within the scientific community. Researchers, professionals, and students can benefit from the convergence of knowledge that this journal facilitates from 2007 to 2024, fostering advancements in understanding viral pathogens and innovative treatment strategies that are increasingly vital to public health efforts globally.

GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE is a prominent scholarly journal published by CESKA LEKARSKA SPOLECNOST J EV PURKYNE in the Czech Republic. With an ISSN of 1210-7913, this journal has been at the forefront of research since its inception in 1994, showcasing a rich repository of studies bridging the domains of epidemiology, microbiology, immunology, and infectious diseases, and reflecting advancements over three decades. Although it currently falls within the Q4 category in multiple fields including Epidemiology and Microbiology, the journal serves an essential role in disseminating knowledge and fostering discussions around public health challenges. The contributions made through its pages are vital for researchers, healthcare professionals, and students aiming to enhance their understanding of complex biomedical issues. While it does not offer open access, the journal remains a critical resource in its niches, inviting readers to engage with the latest findings and methodologies reshaping the landscape of health science.